NAMEX VENTURES INC. ANNOUNCES EXECUTION OF A DISTRIBUTION AGREEMENT WITH PFT COVID, LLC of Rockwall, Texas to distribute APT(tm) T3X

Winnipeg Manitoba (Viz Release) September 25, 2020 – – Namex Ventures Inc. APT(tm) T3X is a proprietary barrier application that decreases the viral load of exposure against COVID-19 (SARS-CoV-2),other coronaviruses and Influenza virus.  The distribution agreement covers Canada, Jamaica and other Caribbean Islands, the United Kingdom, United Arab Emirates, Singapore and India.

A Powerful Preventative in the Fight against Covid-19, APT(tm) T3X Formulation used as an Intra-nasal Application Provides an Additional Layer of Protection by Decreasing the Viral Load of Exposure

PFT COVID, LLC, is a subsidiary of Patient Focused Tele-Health, LLC (PFTH)

PFTH has been granted the worldwide exclusive license for the COVID preventative formulation, developed by Advanced Penetration Technology LLC.

Advanced Penetration Technology, LLC, (APT) a Texas- and Indiana-based company (http://www.aptt3x.com) that specializes in innovative healthcare solutions for patients utilizing non-prescription, Over the Counter (OTC) products.  APT has been provided results of an independent laboratory evaluation of a topical medical formulation that mitigates or neutralizes infectivity of SARS-CoV-2 virus (COVID-19) in vitro. The focus is preventing COVID-19 from entering the body through the nasal passages, thereby significantly reducing the likelihood of people becoming infected with the virus.

“We believe this is the breakthrough that will reduce the likelihood of becoming infected with SARS-CoV-2 (COVID) through the nose, which is now recognized as the primary site of infection,” said Dr. Brian J. Huber, the CEO and Founder of APT, LLC. “While the world anxiously awaits a vaccine, APT(tm) T3X is the type of protection so many have been hoping for. This could be an active first line of defense against the COVID virus. It is a powerful and effective layer of prevention.”

Dr. Huber also stated, “Colleges have been disrupted. Schools and teachers have been disrupted. Small and large business have been disrupted. Sports, worship, work and general social interactions have, and will continue to be, disrupted until there is a vaccine. In the meantime, APT(tm) T3X provides the type of protection that could be key to our schools and economy reopening fully and safely.”

A London-based independent research laboratory, Virology Research Services Ltd., evaluated the in vitro anti-viral impact of the product, named APT(tm) T3X, against the SARS-CoV-2 virus, NL63 coronavirus and Influenza A virus and concluded that it is a highly effective formulation in preventing infectivity. The research concludes that APT(tm) T3X effectively neutralizes viral infectivity within seconds. This research was funded by Patient Focused Tele-Health, LLC.

“Under the conditions tested, APT T3X displays a 99.9% virucidal activity against human SARS-CoV-2 coronavirus,” the report concluded. This formulation will also neutralize infectivity of Influenza viruses, which are the next seasonal illness for students, healthcare workers and the general public to consider.

The testing was performed over four months, May through August, 2020. All definitive anti-viral assays were performed in triplicate.

APT(tm) T3X is a topical liquid formulation applied inside the nasal passages by a cotton tip applicator (like a Q-tip(R)) with 3-4 drops on the tip. People simply need to “paint” the nasal channels and inside of their nostrils with the cotton tip applicator.

By coating the nasal passages, a barrier is formed that will reduce the viral load of exposure. The efficacy of APT(tm) T3X is due to APT’s proprietary formulation combined with Tetracycline hydrochloride as the active pharmaceutical ingredient. The product is registered with the Federal Drug Administration as an over-the-counter ointment, used in an off-label manner to decrease the viral load of exposure.

The product was initially developed eight years ago for resistant-bacterial infections, but its formulation additionally provides powerful anti-fungal and anti-viral therapies.  In over 8 years of use it has no documented side effects.

“As this virus took off last Spring, we thought the APT(tm) T3X product could prevent or reduce the ability of the virus to enter the human body through the nose,” Huber said. “We felt it was our call-to-duty to investigate. That’s why we sent APT(tm) T3X to an independent virology lab for proper antiviral evaluation and tests. We’re highly encouraged by the laboratory results and conclusions. The APT(tm) T3X is a highly effective antiviral formulation. Until there is a vaccine, the best thing we can do is prevent the virus from entering someone’s body through the nose, which is what our product does.”

It’s all about the nose. Recent studies by the Massachusetts Institute of Technology (MIT) and Johns Hopkins Medicine studies concluded that people contract COVID-19 and other viruses primarily through the nose. The NOSE is the primary site of infectivity and replication for COVID-19 that enables this to spread elsewhere in the body. In addition to following CDC guidelines, the APT(tm) T3X provides ANOTHER layer of needed preventative protection.

Website:  www.aptt3x.com

About Advanced Penetration Technology, LLC:

Advanced Penetration Technology, LLC, is an Indiana- and Texas-based company that creates new solutions for areas of patient care utilizing over-the-counter product platforms. Its products have been used to treat wounds, burns, acne and other conditions. Founded in in 2016, APT strives to provide access to highly effective care at the primary and home levels on a global scale. The Advanced Penetration Technology has been shown in preliminary laboratory testing to provide significantly improved penetration of certain medications at the target site, allowing for improved effectiveness in certain topically applied products and creating a more optimal environment for a more rapid healing process.

About Brian J. Huber D.V.M., A.B.V.P:

Dr. Brian J. Huber is the CEO and Founder of Advanced Penetration Technology (APT), LLC. A graduate of Kansas State University where he received his doctorate in veterinary medicine, Dr. Huber has over 30 years of experience working in the human medical and veterinary arenas. Among his current duties with APT, Dr. Huber also serves as Chief Medical Officer at BioPharma Products, LLC, and the President of Aliquis Telepresence: Division of Hodei Technology. Dr. Huber’s breadth of experiences across many healthcare continuums, has provided insight and access to technology and business opportunities in both human and veterinary businesses.

About Namex Ventures Inc.

The Company was a former junior mineral exploration company. The Company has identified a new business and Namex is now focusing on cultivating and processing hemp for the extraction of CBD for sale in the rapidly expanding health and wellness market.  The Company continues to identify additional strategic alliances and partnerships to further advance business opportunities.  The Company continues to evaluate funding sources to advance its business plans. For additional information, please visit us at www.namx.ca

Namex Ventures Inc.

George Gale
CEO
Tel: 204-691-3775
E-mail: georgegalevp@yahoo.ca

Lionel Gosselin
President
204-691-3775
E-mail: info@namx.ca

Forward-looking Statements

No Exchange has reviewed or accepts responsibility for the adequacy or accuracy of this release. This release includes certain statements that may be deemed “forward-looking statements”. All statements in this release, other than statements of historical facts that address future production, and events or developments that the Company expects are forward-looking statements. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in the forward-looking statements. Factors that could cause actual results to differ materially from those in forward looking statements include market prices, continued availability of capital and financing, and general economic, market or business conditions. Investors are cautioned that any such statements are not guarantees of future performance and those actual results or developments may differ materially from those projected in the forward-looking statements. For more information on the Company, Investors should review the Company’s registered filings that are available at www.sedar.com.